Quantcast

Latest Darbepoetin alfa Stories

2010-05-20 17:08:00

THOUSAND OAKS, Calif., May 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from studies involving nine molecules in the Company's oncology portfolio will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4( )- 8, 2010 in Chicago. "Cancer is a complex disease that requires a comprehensive approach. Our goal is to help patients battle cancer by leveraging our understanding of cancer biology and pharmacogenomics to...

2010-03-03 09:01:40

STANFORD, Calif. -- A new study helps dispel mounting confusion over the safety of blockbuster anemia drugs "” erythropoiesis-stimulating agents "” for people with kidney disease requiring dialysis, as federal regulators prepare to decide whether to impose additional restrictions on their use. ESAs are the most expensive drugs reimbursed by Medicare in patients requiring long-term dialysis, costing the agency nearly $2 billion annually. The new study, to be published March 3...

2010-02-16 10:54:00

SILVER SPRING, Md., Feb 16 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs). For patients with cancer, the program is also designed to help ensure the appropriate administration of these drugs, which they receive to treat anemia that can occur as a result of chemotherapy. (Logo:...

2010-02-16 08:58:00

HORSHAM, Pa., Feb. 16 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. and Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include PROCRIT® (Epoetin alfa), Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa). The FDA has determined that a REMS is necessary for ESAs to ensure the...

2010-02-16 08:50:00

THOUSAND OAKS, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa). The FDA has determined that a REMS is...

2010-01-06 15:22:00

EXTON, Pa., Jan. 6 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the availability of its TreatmentTrends®: US Nephrology, EU Nephrology, and Canadian Nephrology publications. The reports are based on responses to online surveys completed by over 300 Nephrologists in the US, over 200 Nephrologists in Europe (UK, France, Germany, Italy and Spain) and 40 Nephrologists in Canada during November / December 2009. A similar report on the renal anemia...

2009-12-23 09:05:38

An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising. Darbepoetin alfa is one of a class of drugs used to increase red blood cells in patients with type 2 diabetes, chronic kidney disease and anemia, but in a study of 4,038 patients, it did little to reduce cardiovascular problems, death or even the need for dialysis....

2009-12-02 16:53:00

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Growth Factors (Blood And Tissue) - A World Report http://www.reportlinker.com/p0164229/Growth-Factors-Blood-And-Tissue---A-World-Report.html Age-related conditions such as Alzheimer's disease, malignancies, trauma and autoimmune disorders necessitate the development of less-invasive and more effective therapies. Growth factors (blood and tissue) have made an...

2009-11-30 07:51:00

THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition...

2009-11-16 07:00:00

Study highlights: - Risks of an anemia drug appear to outweigh its benefits among diabetic patients with kidney disease, anemia and a history of cardiovascular disease or stroke. - This first large, randomized, placebo-controlled trial finds drug raises hemoglobin levels and reverses anemia but does not improve patient cardiovascular outcomes. - Treatment with darbepoetin alfa in patients with type 2 diabetes, chronic kidney disease and moderate anemia doubled the risk of stroke compared...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related